Drug that alters gut microbiome shows promise for relieving long COVID symptoms

In a study recently published in The Lancet Infectious Disease, researchers from the Chinese University of Hong Kong discovered that the synbiotic drug SIM01 relieves multiple symptoms of long COVID, or post-acute COVID-19 syndrome (PACS).

SIM01 contains strains of anaerobic Bifidobacterium bacteria (which are probiotics) and soluble fibers (prebiotics) to alter the gut microbiome and possibly modify immune response.